The US Medicare Payment Advisory Commission is finally able to analyze the impact of rebates on drug pricing in the Part D pharmacy benefit program – but will have to adopt a wait-and-see approach to recommending new policies given the expected impact of the Inflation Reduction Act.
MedPAC, which is chartered by Congress to provide recommendations to improve the Medicare program, heard an analysis of some...






